PMID- 28212806
OWN - NLM
STAT- MEDLINE
DCOM- 20170718
LR  - 20180813
IS  - 2210-7762 (Print)
VI  - 210
DP  - 2017 Jan
TI  - Clonal evolution as detected by interphase fluorescence in situ hybridization is 
      associated with worse overall survival in a population-based analysis of patients 
      with chronic lymphocytic leukemia in British Columbia, Canada.
PG  - 1-8
LID - S2210-7762(16)30267-8 [pii]
LID - 10.1016/j.cancergen.2016.10.006 [doi]
AB  - This study evaluates prognostic markers as predictors of clonal evolution (CE) 
      and assesses the impact of CE on overall survival (OS) in a population-based 
      cohort of 159 consecutive eligible patients with chronic lymphocytic leukemia 
      (CLL) obtained from the British Columbia Provincial CLL Database. CE was detected 
      by interphase fluorescence in situ hybridization (FISH) in 34/159 patients (21%) 
      with 65% of CE patients acquiring deletion 17p or 11q. CD38 positive status 
      (>/=30%) on flow cytometry predicted 2.7 times increased risk of high-risk CE 
      (acquisition of deletion 17p or 11q) on multivariate analysis. Prior CLL therapy 
      was not a significant predictor of CE. CE was associated with 4.1 times greater 
      risk of death when analyzed as a time-dependent variable for OS after adjusting 
      for age, lymphocyte count, and FISH timing. High-risk CE was associated with 
      worse OS while acquisition of low/intermediate-risk abnormalities (trisomy 12, 
      deletion 13q, and IGH translocation) had no difference in OS. Our study 
      demonstrates the negative impact of CE detected by FISH on OS in this 
      population-based cohort. These data provide support for repeating FISH testing 
      during CLL follow-up as patients with high-risk CE have reduced survival and may 
      require closer observation.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Huang, Steven J
AU  - Huang SJ
AD  - Division of Hematology, Vancouver General Hospital, University of British 
      Columbia, Vancouver, BC, Canada; Pathology and Laboratory Medicine, Vancouver 
      General Hospital, University of British Columbia, Vancouver, BC, Canada.
FAU - Bergin, Krystal
AU  - Bergin K
AD  - Division of Hematology, Vancouver General Hospital, University of British 
      Columbia, Vancouver, BC, Canada.
FAU - Smith, Adam C
AU  - Smith AC
AD  - Cancer Genetics Laboratory, Pathology and Laboratory Medicine, British Columbia 
      Cancer Agency, University of British Columbia, Vancouver, BC, Canada; The Pele 
      Research Institute, Hospital Pequeno Prinicipe, Brazil.
FAU - Gerrie, Alina S
AU  - Gerrie AS
AD  - Division of Hematology, Vancouver General Hospital, University of British 
      Columbia, Vancouver, BC, Canada; Leukemia/BMT Program of BC, Vancouver General 
      Hospital and British Columbia Cancer Agency, University of British Columbia, 
      Vancouver, BC, Canada.
FAU - Bruyere, Helene
AU  - Bruyere H
AD  - Pathology and Laboratory Medicine, Vancouver General Hospital, University of 
      British Columbia, Vancouver, BC, Canada.
FAU - Dalal, Chinmay B
AU  - Dalal CB
AD  - Division of Hematology, Vancouver General Hospital, University of British 
      Columbia, Vancouver, BC, Canada.
FAU - Sugioka, Daniele K
AU  - Sugioka DK
AD  - The Pele Research Institute, Hospital Pequeno Prinicipe, Brazil.
FAU - Hrynchak, Monica
AU  - Hrynchak M
AD  - Cytogenetics Laboratory, Royal Columbian Hospital, New Westminster, BC, Canada.
FAU - Ramadan, Khaled M
AU  - Ramadan KM
AD  - Division of Hematology, St. Paul's Hospital, University of British Columbia, 
      Vancouver, BC, Canada.
FAU - Karsan, Aly
AU  - Karsan A
AD  - Cancer Genetics Laboratory, Pathology and Laboratory Medicine, British Columbia 
      Cancer Agency, University of British Columbia, Vancouver, BC, Canada.
FAU - Gillan, Tanya L
AU  - Gillan TL
AD  - Pathology and Laboratory Medicine, Vancouver General Hospital, University of 
      British Columbia, Vancouver, BC, Canada.
FAU - Toze, Cynthia L
AU  - Toze CL
AD  - Division of Hematology, Vancouver General Hospital, University of British 
      Columbia, Vancouver, BC, Canada; Leukemia/BMT Program of BC, Vancouver General 
      Hospital and British Columbia Cancer Agency, University of British Columbia, 
      Vancouver, BC, Canada. Electronic address: ctoze@bccancer.bc.ca.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20161103
PL  - United States
TA  - Cancer Genet
JT  - Cancer genetics
JID - 101539150
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - British Columbia/epidemiology
MH  - Clonal Evolution
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Interphase
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*genetics/*mortality
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Survival Analysis
OTO - NOTNLM
OT  - Chronic lymphocytic leukemia
OT  - clonal evolution
OT  - fluorescence in situ hybridization
OT  - overall survival
OT  - population
OT  - prognosis
EDAT- 2017/02/19 06:00
MHDA- 2017/07/19 06:00
CRDT- 2017/02/19 06:00
PHST- 2016/05/11 00:00 [received]
PHST- 2016/08/20 00:00 [revised]
PHST- 2016/10/27 00:00 [accepted]
PHST- 2017/02/19 06:00 [entrez]
PHST- 2017/02/19 06:00 [pubmed]
PHST- 2017/07/19 06:00 [medline]
AID - S2210-7762(16)30267-8 [pii]
AID - 10.1016/j.cancergen.2016.10.006 [doi]
PST - ppublish
SO  - Cancer Genet. 2017 Jan;210:1-8. doi: 10.1016/j.cancergen.2016.10.006. Epub 2016 
      Nov 3.